This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie Grant Agreement No. 956851.

Christer Tannergren

Christer Tannergren, PhD, Principal Scientist in Biopharmaceutics at Oral Product Development, Pharmaceutical Technology & Development, AstraZeneca Gothenburg, Sweden. He received his PhD in Biopharmaceutics at the Department of Pharmacy, Uppsala University, Sweden in 2004. He has held various Biopharmaceutics expert positions and Product Development Lead roles since joining AstraZeneca in 2003. His main areas of research interest include physiologically based biopharmaceutics modelling and regional intestinal absorption/bioavailability as well as development of low solubility and Modified Release drug products. He has co-supervised 3 PhD students and is author of 35 peer-reviewed papers as well as inventor of 1 formulation patent.